Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.73 |
| ▸ | PREP | P48147 | 4/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.68 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.67 |
| ▸ | FAP | Q12884 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | PRSS8 | Q16651 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16670130 | 0.91 | PREP (0.62) | DPP4PREPDPP8DPP7DPP9 | |
| SCHEMBL16670124 | 0.91 | PREP (0.62) | DPP4PREPDPP8DPP7DPP9 | |
| SCHEMBL4955191 | 0.86 | DPP8 (0.71) | DPP4DPP8DPP7ACEPRSS8 | |
| SCHEMBL9040814 | 0.86 | DPP8 (0.71) | DPP4DPP8DPP7ACEPRSS8 | |
| SCHEMBL7326774 | 0.85 | DPP8 (0.70) | DPP4PREPDPP8DPP7ACE | |
| SCHEMBL6167227 | 0.85 | DPP4 (1.00) | DPP4PREPDPP8DPP7DPP9 | |
| SCHEMBL14602203 | 0.83 | DPP4 (0.71) | DPP4PREPDPP8DPP7DPP9 | |
| SCHEMBL9040522 | 0.83 | DPP4 (0.67) | DPP4PREPDPP8DPP7ACE | |
| SCHEMBL9040510 | 0.83 | DPP4 (0.67) | DPP4PREPDPP8DPP7ACE | |
| SCHEMBL7264291 | 0.82 | DPP8 (0.66) | DPP4PREPDPP8DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465891-A4 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARM INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | GUILFORD PHARMACEUTICALS | 2005-03-31 | — | — | US | disclosed |
| EP-1465891-A2 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003057666-A2 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003057144-A2 | CHANGE INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | DPP4, DPP3, DPP7 | DPP4 1/4885PREP 22/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.